BioSpace News Archive

Hitachi to Provide CNAO with Proton Therapy System

Hitachi, Ltd. has entered into an agreement to provide Centro Nazionale di Adroterapia Oncologica with its proton therapy system.

December 8, 2019
·
2 min read
BioMidwest

New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Full results are being highlighted today in an oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition

December 8, 2019
·
18 min read
Biotech Bay

New Data Demonstrate the Continued Clinical Benefit of Fixed-duration, Chemotherapy-free Venclexta-based Treatments in Chronic Lymphocytic Leukemia

In an updated analysis of the CLL14 study, Venclexta plus Gazyva achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukemia

December 8, 2019
·
27 min read
Drug Development

Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data

Innate Pharma SA shared new, long-term data from the pivotal Phase III trial of Lumoxiti at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, USA, which expands on the efficacy results and affirms the manageable safety profile of the medicine.

December 8, 2019
·
7 min read
Drug Development

Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Personalized Manufacture” (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting

Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells

December 8, 2019
·
5 min read
Drug Development

Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

Interim Results Demonstrate Good Tolerability and Clinical Response in Patients with Relapsed/Refractory PTCL and CTCL

December 8, 2019
·
6 min read
Business

Company Profile for Jasper Therapeutics, Inc

Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning agents and therapeutics to allow for expanded use of curative hematopoietic stem cell transplants and gene therapies.

December 8, 2019
·
1 min read
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting

Responses observed at all dose levels in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), including patients with BTK Resistance, BTK Intolerance, and BCL2 Resistance

December 8, 2019
·
9 min read
Pharm Country

Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting

Heavily pre-treated patients with chronic lymphocytic leukemia receiving liso-cel achieved durable complete responses, including undetectable minimal residual disease

December 8, 2019
·
11 min read
Policy

Public Health Notice: Outbreak of E. coli infections linked to Fresh Express brand Sunflower Crisp Chopped Salad Kits

The Public Health Agency of Canada is collaborating with provincial public health partners, the Canadian Food Inspection Agency and Health Canada to investigate an outbreak of E. coli infections occurring across five eastern provinces.

December 8, 2019
·
5 min read